List of Excipients in Branded Drug BRETYLIUM TOSYLATE

Generic Drugs Containing BRETYLIUM TOSYLATE

Company	Ingredient	NDC	Excipient
ANI Pharmaceuticals Inc	bretylium tosylate	62559-870	HYDROCHLORIC ACID
ANI Pharmaceuticals Inc	bretylium tosylate	62559-870	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BRETYLIUM TOSYLATE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Bretylium Tosylate Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Bretylium tosylate is an established injectable antiarrhythmic with limited current commercial availability and no obvious active-ingredient patent barrier. The strongest opportunity is a modern, ready-to-use intravenous product designed for emergency cardiac care, hospital stockpiling, and potential non-U.S. markets. Excipient selection should prioritize chemical stability, low particulate burden, rapid preparation, compatibility with emergency infusion systems, and a label suitable for critical-care use.

The commercial case depends more on regulatory execution, supply reliability, and institutional adoption than on exclusivity from the bretylium molecule itself. A 505(b)(2) strategy, where available, could leverage historical safety and clinical information while supporting a differentiated formulation, container, presentation, or dosing system.

What is bretylium tosylate used for?

Bretylium tosylate is a quaternary ammonium antiarrhythmic historically used for ventricular fibrillation and life-threatening ventricular tachyarrhythmias. It inhibits adrenergic neuronal transmission and affects cardiac action-potential conduction. The drug was administered intravenously or intramuscularly in emergency settings, with intravenous use requiring attention to hypotension and infusion technique.

Bretylium was included in earlier advanced cardiac life-support protocols, but its availability declined because of manufacturing and supply constraints. Current resuscitation guidelines emphasize amiodarone and lidocaine for refractory ventricular fibrillation or pulseless ventricular tachycardia. Bretylium is not a routine first-line antiarrhythmic in current U.S. emergency practice.[1]

Historically relevant attributes include:

Attribute	Bretylium tosylate
Active pharmaceutical ingredient	Bretylium tosylate
Pharmacologic class	Antiarrhythmic, adrenergic neuron-blocking agent
Primary historical use	Ventricular fibrillation and ventricular tachyarrhythmias
Dosage form	Sterile parenteral injection
Administration	Intravenous or intramuscular, depending on product and label
Key safety concerns	Hypotension, nausea, vomiting, bradycardia, renal clearance considerations
Current U.S. role	Limited or unavailable in routine clinical use
Main commercial issue	Reliable supply and regulatory redevelopment

What excipients are appropriate for bretylium tosylate injection?

A simple aqueous formulation is the most commercially defensible starting point. Bretylium tosylate is an ionic, water-soluble compound, so a suspension, lipid emulsion, or complex solubilizer system would add development risk without a clear clinical advantage.

Recommended excipient architecture

Formulation function	Candidate approach	Commercial rationale
Vehicle	Water for Injection	Standard parenteral vehicle with broad regulatory familiarity
Tonicity	Sodium chloride or another validated tonicity agent	Supports intravenous tolerability and predictable osmolality
pH control	Minimal phosphate, citrate, or other compatible buffer, if required	Limits pH drift during storage
Antioxidant	Avoid unless forced by degradation data	Reduces excipient burden and compatibility risk
Preservative	Prefer preservative-free single-dose presentation	Better fit for emergency IV use and high-risk patients
Chelator	Consider only if metal-catalyzed degradation is demonstrated	Avoids unnecessary complexity
Container closure	Type I glass vial, polymer vial, or prefilled syringe after compatibility testing	Supports stability, emergency access, and distribution

The formulation should not assume that a buffer, antioxidant, or preservative is beneficial. Each excipient should be justified by forced-degradation, extractables and leachables, particulate, sterility, and container-closure data.

Why a preservative-free presentation is preferable

A preservative-free product would align with modern hospital expectations for intravenous emergency medicines. A single-dose vial or prefilled syringe would reduce contamination risk and eliminate the need to justify repeated-dose use from a multidose container.

A multidose vial could lower packaging cost, but its benefits are weaker in a resuscitation setting. It would require a preservative system, multidose in-use stability, repeated-puncture validation, and a label that addresses handling after opening. Those requirements could complicate approval and reduce compatibility with automated emergency medication systems.

Is sodium chloride the best tonicity agent?

Sodium chloride is the most conventional candidate, but the final concentration should be driven by osmolality, chemical stability, injection volume, and compatibility with common infusion solutions. A hypertonic concentrate may be commercially acceptable if the label clearly requires dilution before infusion. A ready-to-administer formulation would offer stronger differentiation but could require a larger container volume or a more concentrated formulation.

The product should be evaluated in commonly used diluents, including:

• 0.9% sodium chloride injection
• 5% dextrose injection
• Other hospital-standard compatible infusion fluids where clinically relevant

Compatibility studies should examine precipitation, color, pH, assay, degradants, visible and subvisible particles, and adsorption to infusion bags and administration sets.

What formulations are protected by bretylium tosylate patents?

The bretylium tosylate active ingredient is an old pharmaceutical substance, so primary composition-of-matter exclusivity is not expected to provide meaningful protection for a new U.S. product. The commercially relevant intellectual-property opportunity would instead involve formulation, packaging, administration, manufacturing, or device claims.

Potentially protectable features include:

1. A stable ready-to-use aqueous formulation with defined pH and osmolality.
2. A low-volume concentrated injection that remains chemically stable without preservatives.
3. A prefilled syringe or autoinjector adapted for emergency administration.
4. A formulation with extended room-temperature stability for crash carts and ambulances.
5. A manufacturing process that controls impurities or improves sterilization compatibility.
6. A container-closure system that limits adsorption, leachables, or moisture ingress.
7. A kit combining bretylium tosylate with compatible diluent and administration components.

These claims would need a demonstrated technical effect. A patent that merely substitutes one conventional excipient for another is vulnerable to obviousness challenges, particularly for an old injectable active ingredient.

When does bretylium tosylate lose exclusivity?

Bretylium tosylate has no practical new-molecule exclusivity remaining. Historical product approvals and earlier patents do not create a modern commercial monopoly over the active ingredient.

The relevant exclusivity analysis is therefore product-specific:

Exclusivity category	Current commercial significance
Active-ingredient patent	Unlikely to block development
New chemical entity exclusivity	Expired or inapplicable
Historical formulation patents	Must be checked individually; unlikely to control the basic injection
New formulation patent	Potentially available for a differentiated product
Orphan-drug exclusivity	Possible only if a qualifying current development receives designation and approval
Pediatric exclusivity	Not expected to be relevant without a qualifying current product
Regulatory exclusivity under a reformulation pathway	Depends on the approved product and legal pathway

A developer should treat bretylium as an off-patent active ingredient with potential formulation-level exclusivity, not as a protected branded asset.

What is the FDA regulatory status of bretylium tosylate?

The principal U.S. regulatory issue is product availability, not whether bretylium has historical FDA recognition. Bretylium products were previously marketed in the United States, but routine commercial availability has been limited. Current resuscitation protocols do not place bretylium alongside amiodarone and lidocaine as standard U.S. options.[1]

A new sponsor would likely need one of the following approaches:

505(b)(2) application

A 505(b)(2) application may be appropriate if the sponsor can rely partly on prior FDA findings or published literature while developing a new dosage form, strength, presentation, or formulation. The viability of this route depends on the precise regulatory history, the availability of reference information, and the extent of new clinical evidence required.

A 505(b)(2) strategy could support:

• A new ready-to-use injection
• A prefilled syringe
• A revised concentration
• A new container presentation
• A formulation with improved storage or administration characteristics

Abbreviated new drug application

An ANDA may be possible only if an appropriate reference-listed drug and a pharmaceutically equivalent product are available for comparison. If the historical reference product is discontinued, unavailable, or unsuitable for current development, the ANDA pathway may be less practical than a 505(b)(2) application.

New drug application

A full NDA could be required if the sponsor cannot rely adequately on prior findings or if the proposed product differs materially from historical products. That route would increase clinical, regulatory, and commercial risk.

How many patents cover bretylium tosylate?

No meaningful blocking patent estate is apparent for the basic bretylium tosylate injection based on the drug’s age and historical use. The relevant patent search should focus on current formulation and delivery claims rather than the expired active-ingredient estate.

A diligence review should cover:

• U.S. Patent and Trademark Office records
• FDA Orange Book listings
• FDA Drugs@FDA records
• International patent families
• Formulation patents covering sterile aqueous injections
• Device patents covering emergency syringes or autoinjectors
• Manufacturing patents involving sterilization and impurity control

The Orange Book may not provide a useful current listing if there is no active reference product with listed patents. Absence of an Orange Book-listed patent does not eliminate the need to review non-Orange Book patents, pending applications, or non-U.S. rights.

What patent litigation and Paragraph IV risks exist?

A generic or 505(b)(2) bretylium product would face relatively low Paragraph IV risk from the old active ingredient. The more credible dispute would involve a later formulation patent or device patent owned by a developer that commercializes a differentiated product.

Potential dispute areas include:

• Whether a proposed product infringes a formulation patent
• Whether a ready-to-use product is obvious over historical bretylium injections
• Whether a prefilled syringe is covered by a device claim
• Whether a process claim is infringed during sterile manufacture
• Whether a patent listed for a reference product is properly Orange Book-listed

A sponsor can reduce litigation exposure by developing a formulation with a distinct excipient profile, container system, concentration, and administration method. A freedom-to-operate review should separate expired historical patents from live patents that claim specific formulation parameters.

How strong is the patent estate for bretylium tosylate?

The underlying patent estate is weak for exclusivity but potentially adequate for a narrow product-differentiation strategy. The strongest claims would likely require a measurable performance advantage, such as extended stability, improved emergency usability, lower preparation time, or improved compatibility with infusion equipment.

Patent-strength assessment

Asset type	Likely strength	Commercial value
Bretylium molecule	Low	Minimal
Basic aqueous injection	Low to moderate	Limited unless supported by unexpected stability
Preservative-free ready-to-use product	Moderate	Meaningful if stability and usability are superior
Prefilled syringe	Moderate	Stronger if device and formulation are integrated
Room-temperature stockpile formulation	Moderate to strong	High for hospitals and emergency agencies
Manufacturing impurity-control process	Moderate	Useful for supply differentiation
Combination emergency kit	Variable	Commercially useful, but claim scope may be narrow

What commercial opportunities exist for bretylium tosylate?

The best opportunity is a supply-constrained emergency medicine product with operational advantages. The product should solve a current hospital problem rather than compete solely on price.

Hospital emergency departments and cardiac arrest carts

A prefilled syringe or compact single-dose vial could reduce preparation time and medication errors. Institutional buyers may value predictable availability, long shelf life, and simple storage more than a novel pharmacologic profile.

Ambulance and emergency medical services

EMS systems need small, durable presentations that tolerate temperature variation and rapid deployment. A ready-to-use product could be more attractive than a concentrated vial requiring dilution.

Government and strategic stockpiles

Bretylium’s historical role in severe ventricular arrhythmias could support procurement discussions with government agencies, military medical systems, and disaster-response organizations. Stockpile value would depend on shelf life, supply continuity, and inclusion in applicable treatment protocols.

International markets

The commercial case may be stronger in jurisdictions where bretylium remains recognized or where alternative antiarrhythmics are costly or difficult to obtain. Geographic expansion would require country-specific review of registration status, pharmacopoeial standards, local reference products, and supply-chain requirements.

Veterinary emergency medicine

Veterinary use could represent a secondary market, but it would require separate assessment of clinical demand, dosing, regulatory status, and animal-health distribution channels. It should not be assumed that human injectable approval supports veterinary commercialization.

How does bretylium compare with amiodarone and lidocaine?

Bretylium would enter a market dominated by established alternatives. Amiodarone has broad use in ventricular arrhythmias, while lidocaine remains an accepted alternative in certain resuscitation settings. Both have established supply chains and greater current guideline familiarity.

Factor	Bretylium tosylate	Amiodarone	Lidocaine
Current guideline familiarity	Limited	High	High
Historical role	Ventricular arrhythmias	Broad antiarrhythmic use	Ventricular arrhythmias
Commercial availability	Limited or variable	Broad	Broad
Differentiation opportunity	High through presentation and supply	Lower	Lower
Development risk	Regulatory and adoption risk	Competitive risk	Competitive risk
Main value proposition	Backup supply and emergency readiness	Established clinical use	Familiar alternative

Bretylium would need a specific positioning strategy. A sponsor should not rely on a broad claim that the product is clinically superior unless new comparative evidence supports it. The more defensible position is a reliable, rapidly deployable option for selected refractory ventricular arrhythmias and institutional preparedness.

What manufacturing and intellectual-property barriers affect commercialization?

The active ingredient is not likely to be the main manufacturing bottleneck. The greater risks are qualified API supply, impurity control, sterile filling capacity, container compatibility, and long-term stability.

A commercial manufacturing plan should address:

• At least two qualified API sources where feasible
• Control of related substances and residual solvents
• Consistent salt form and water content
• Sterile filtration or terminal sterilization strategy
• Compatibility with the selected container closure
• Stability at refrigerated and room-temperature conditions
• Freeze-thaw and shipping excursion performance
• Particulate and visible foreign matter control
• Supply continuity for emergency procurement

A second-source strategy is especially important because historical bretylium availability was affected by supply limitations. A product that receives approval but cannot maintain inventory would have limited institutional value.

What generic launch scenarios exist for bretylium tosylate?

Three launch models are commercially plausible.

Low-cost conventional vial

This model uses a standard sterile vial and conventional labeling. It minimizes development cost but provides little differentiation and exposes the sponsor to price competition.

Ready-to-use emergency syringe

This model carries higher packaging and device-development costs but can command stronger institutional value through reduced preparation time and lower dosing error risk.

Stockpile-focused extended-stability product

This model targets hospitals, government buyers, and emergency systems. The commercial proposition depends on long dating, broad storage conditions, and dependable supply rather than high routine prescription volume.

The most attractive launch sequence would typically begin with a conventional single-dose injection, followed by a prefilled or ready-to-administer presentation if demand and regulatory feedback support expansion.

What is the revenue exposure and market size?

Bretylium is unlikely to support a large routine outpatient market. Revenue would depend on institutional purchasing, emergency medicine contracts, government procurement, and international sales.

Commercial exposure is sensitive to four variables:

1. Whether U.S. resuscitation protocols regain a role for bretylium.
2. Whether hospitals accept the product into formularies and crash carts.
3. Whether the sponsor secures reliable API and sterile manufacturing capacity.
4. Whether a differentiated presentation supports pricing above a basic generic injection.

A conventional product could face low annual unit volume but still have strategic value if it secures sole-source or shortage-response contracts. A ready-to-use product would have a stronger margin opportunity, but the market would remain dependent on clinical adoption and procurement policy.

Key Takeaways

• Bretylium tosylate is an old, off-patent antiarrhythmic with limited current U.S. commercial availability.
• The strongest development concept is a preservative-free sterile aqueous injection.
• A single-dose vial is the lowest-risk formulation; a prefilled syringe offers greater differentiation.
• Excipients should be minimized and justified by stability, tonicity, compatibility, or container-closure data.
• The principal commercial barriers are regulatory redevelopment, clinical adoption, supply continuity, and sterile manufacturing.
• A 505(b)(2) strategy may be more practical than an ANDA if no suitable current reference product is available.
• Patent value is more likely to arise from formulation, packaging, device, stability, or manufacturing claims than from the active ingredient.
• The main competitors are amiodarone and lidocaine, both of which have stronger current guideline positions.
• The best commercial customers are hospitals, EMS systems, government stockpiles, and selected international markets.
• The product should be positioned around availability, rapid administration, and emergency preparedness rather than assumed clinical superiority.

FAQs

Is bretylium tosylate still FDA approved?

Historical bretylium products received U.S. regulatory approval, but current commercial availability and reference-product status are limited. A new sponsor would need to confirm the applicable regulatory pathway and current FDA product records.

Can bretylium tosylate be reformulated as a prefilled syringe?

Yes, a prefilled syringe is technically plausible if the drug remains stable in the selected polymer or glass system and the formulation meets sterility, particulate, extractables, leachables, and device-performance requirements.

Does bretylium tosylate have biosimilar risk?

No. Bretylium tosylate is a small-molecule active ingredient, not a biologic. The relevant competitive threat is generic or 505(b)(2) entry, not biosimilar substitution.

What is the best excipient strategy for a bretylium emergency injection?

The preferred starting strategy is Water for Injection with the minimum amount of tonicity agent and, only if required by data, a compatible buffer. A preservative-free single-dose presentation is generally better aligned with emergency intravenous use.

Can a new bretylium formulation receive patent protection?

Potentially. Protection is more credible for a formulation or delivery system that demonstrates unexpected stability, improved usability, extended storage, reduced preparation time, or a measurable compatibility advantage. Basic use of conventional excipients is less likely to produce strong patent claims.

References

1. American Heart Association. (2020). 2020 American Heart Association guidelines for CPR and ECC: Adult advanced life support. Circulation, 142(Suppl. 2).

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. National Library of Medicine. (n.d.). Bretylium tosylate. PubChem. https://pubchem.ncbi.nlm.nih.gov/

5. United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.